Literature DB >> 23597973

Mucopolysaccharidoses and other lysosomal storage diseases.

Christina Lampe1, Cinzia Maria Bellettato, Nesrin Karabul, Maurizio Scarpa.   

Abstract

Mucopolysaccharidosis and other lysosomal storage diseases are rare, chronic, and progressive inherited diseases caused by a deficit of lysosomal enzymes. Patients are affected by a wide variety of symptoms. For some lysosomal storage diseases, effective treatments to arrest disease progression, or slow the pathologic process, and increase patient life expectancy are available or being developed. Timely diagnosis is crucial. Rheumatologists, orthopedics, and neurologists are commonly consulted due to unspecific musculoskeletal signs and symptoms. Pain, stiffness, contractures of joints in absence of clinical signs of inflammation, bone pain or abnormalities, osteopenia, osteonecrosis, secondary osteoarthritis or hip dysplasia are the alerting symptoms that should induce suspicion of a lysosomal storage disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23597973     DOI: 10.1016/j.rdc.2013.03.004

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  15 in total

1.  A non-BRICHOS SFTPC mutant (SP-CI73T) linked to interstitial lung disease promotes a late block in macroautophagy disrupting cellular proteostasis and mitophagy.

Authors:  Arie Hawkins; Susan H Guttentag; Robin Deterding; William K Funkhouser; Jennifer L Goralski; Shampa Chatterjee; Surafel Mulugeta; Michael F Beers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-24       Impact factor: 5.464

Review 2.  Assessment, pharmacological therapy and rehabilitation management of musculoskeletal pain in children with mucopolysaccharidoses: a scoping review.

Authors:  R Gnasso; B Corrado; I Iommazzo; F Migliore; G Magliulo; B Giardulli; C Ruosi
Journal:  Orphanet J Rare Dis       Date:  2022-07-08       Impact factor: 4.303

3.  Ultrasonographic Features of Hip Joints in Mucopolysaccharidoses Type I and II.

Authors:  Zbigniew Żuber; Agnieszka Jurecka; Agnieszka Różdżyńska-Świątkowska; Agata Migas-Majoch; Agnieszka Lembas; Beata Kieć-Wilk; Anna Tylki-Szymańska
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

4.  Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid.

Authors:  Emanuele Persichetti; Davide Chiasserini; Lucilla Parnetti; Paolo Eusebi; Silvia Paciotti; Claudia De Carlo; Michela Codini; Nicola Tambasco; Aroldo Rossi; Omar M A El-Agnaf; Omar M El Agnaf; Paolo Calabresi; Tommaso Beccari
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

5.  Prevalence of scoliosis in Williams-Beuren syndrome patients treated at a regional reference center.

Authors:  Marcelo Loquette Damasceno; Alexandre Fogaça Cristante; Raphael Martus Marcon; Tarcísio Eloy Pessoa de Barros Filho
Journal:  Clinics (Sao Paulo)       Date:  2014-07       Impact factor: 2.365

6.  The Complexity of Pain Management in Children Affected by Mucopolysaccharidoses.

Authors:  Sabrina Congedi; Chiara Di Pede; Maurizio Scarpa; Angelica Rampazzo; Franca Benini
Journal:  Case Rep Pediatr       Date:  2017-04-03

Review 7.  Diagnostic and treatment strategies in mucopolysaccharidosis VI.

Authors:  Filippo Vairo; Andressa Federhen; Guilherme Baldo; Mariluce Riegel; Maira Burin; Sandra Leistner-Segal; Roberto Giugliani
Journal:  Appl Clin Genet       Date:  2015-10-30

8.  Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment.

Authors:  Gianluigi Mazzoccoli; Rosella Tomanin; Tommaso Mazza; Francesca D'Avanzo; Marika Salvalaio; Laura Rigon; Alessandra Zanetti; Valerio Pazienza; Massimo Francavilla; Francesco Giuliani; Manlio Vinciguerra; Maurizio Scarpa
Journal:  BMC Med Genomics       Date:  2013-10-02       Impact factor: 3.063

9.  Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment.

Authors:  Michael Frohbergh; Yi Ge; Fanli Meng; Nesrin Karabul; Alexander Solyom; Alon Lai; James Iatridis; Edward H Schuchman; Calogera M Simonaro
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

10.  Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs.

Authors:  Calogera M Simonaro; Shunji Tomatsu; Tracy Sikora; Francyne Kubaski; Michael Frohbergh; Johana M Guevara; Raymond Y Wang; Moin Vera; Jennifer L Kang; Lachlan J Smith; Edward H Schuchman; Mark E Haskins
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.